NCT05938426Unknown不适用
Digital Therapeutics (ET-101) Research on Efficiency and Safety About Mild Cognitive Impairment, Randomized, Sham Device, Assessor-blinded, Multi-center Pivotal Study
Emocog Inc.2 个研究点 分布在 2 个国家目标入组 100 人开始时间: 2023年6月8日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 100
- 试验地点
- 2
- 主要终点
- Proportion of subjects with the same or reduced ADAS-cog14 score
研究概览
简要总结
The purpose of this study is to evaluate the efficiency and safety of a digital therapeutics(ET-101) for mild cognitive impairment (MCI).
This is a randomized, sham-controlled, assessor-blinded, 24-week parallel study.
100 MCI patients will be randomly assigned to two groups. The control group will be provided with a sham device.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 55 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •55-85 years old
- •Patients diagnosed with mild cognitive impairment according to Petersen criteria
- •A person with subjective memory complaints
- •Memory degradation of z-score ≤ -1 from the normal range of age, gender, and level of education in the memory area of the CREAD-NP or SNSB battery
- •The functional performance of overall cognitive function and daily life ability is sufficiently preserved.
- •Not dementia
- •MMSE 27 or less
- •Adequate vision and hearing for clinical trial
- •Global CDR 0.5
- •If approved AD treatment drugs(AChEI, memantine, or both) are being administered, they should be administered at a stable dose for at least 12 weeks prior to randomization.
- •Have an identified trial partner (defined as someone who can assist the subject during the trial and spends at least 8 hours per week with the subject). The test partner must provide informed consent. This partner must also be willing and able to provide follow-up information to the subject during the trial. In the opinion of the investigator, the trial partner should spend sufficient time with the subject on a regular basis to ensure that the trial requirements are met. The permanent study partner does not have to live in the same residence as the subject. For study partners not residing with the subject, the investigator should ensure that the subject can easily contact the study partner while the study partner is not with the subject. If it is uncertain whether a subject's care arrangement is suitable for selection, the investigator should discuss this with the Medical Monitor. The trial partner should participate directly in visits where the clinical evaluation of CDR, EQ-5D, ADCS MCI-ADL are performed.
- •No difficulty in using mobile applications using smartphone
- •A person who owns his/her smartphone
- •A person who can call his/her guardian using smartphone by himself/herself
- •No difficulty in reading and writing Korean
- •Willingness and ability to comply with all aspects of the clinical trial protocol
排除标准
- •History of a transient ischemic attack(TIA), stroke, seizure within 12 months
- •Psychiatric symptoms that include;
- •History of diagnosis of psychiatric disorders or symptoms that may interfere with the subject's testing procedure (e.g., psychosis, major depression)
- •Responding "yes" to item 4 or 5 to suicidal ideation part of C-SSRS or any suicidal behavior within 6 months prior to screening, at screening or at randomization visit, or being hospitalized or treated for suicidal behavior in the past 5 years prior to screening
- •All other clinically significant abnormalities, such as
- •Physical examinations, neurological examinations, and vital signs at screening or baseline that, in the opinion of the investigator, may require additional examination or treatment that may interfere with the study procedure or safety
- •Other medical conditions (e.g., heart, respiratory, gastrointestinal, kidney disease) that are not adequately stable controlled or that, in the investigator's opinion, may affect the safety of the subject or interfere with the evaluation of the trial
- •A known or suspected history of drug or alcohol abuse or dependence within 2 years prior to screening
- •Prohibited concomitant medication
- •Surgery that requires general anesthesia is scheduled during the trial period.If only local anesthesia is required and the surgery is the day case without hospitalization after surgery or if, in the opinion of the investigator, the operation does not interfere with the test procedure and the safety of the subject, they should not be excluded
- •History of any type(online/offline) of cognitive intervention or participation in clinical trial regarding cognitive intervention within 12 months
研究组 & 干预措施
Sham Device
Sham Comparator
Sham group
干预措施: Sham Device (Device)
结局指标
主要结局
Proportion of subjects with the same or reduced ADAS-cog14 score
时间窗: Baseline compared to month 6 (24 weeks)
The 14 items of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog14): Total scores range from 0 to 90, with higher scores indicating more worsening. Compare the proportion of subjects with the same or reduced ADAS-cog14 score between ET-101 and Sham group.
次要结局
- Change in CDR-SB(Baseline compared to month 3 (12 weeks), Baseline compared to month 6 (24weeks), month 3 compared to month 6 (12 weeks))
- Change in DSC(Baseline compared to month 3 (12 weeks), Baseline compared to month 6 (24weeks), month 3 compared to month 6 (12 weeks))
- Proportion of subjects with the same or reduced ADAS-cog14 score(Baseline compared to month 3 (12 weeks), month 3 compared to month 6 (12 weeks))
- Proportion of subjects with decreased ADAS-Cog scores each at 0, 1, 2, 3, 4, 5 or more points.(Baseline compared to month 3 (12 weeks), Baseline compared to month 6 (24weeks), month 3 compared to month 6 (12 weeks))
- Change in ADCS-ADL(Baseline compared to month 3 (12 weeks), Baseline compared to month 6 (24weeks), month 3 compared to month 6 (12 weeks))
- Change in K-MMSEII(Baseline compared to month 3 (12 weeks), Baseline compared to month 6 (24weeks), month 3 compared to month 6 (12 weeks))
- CIBIC-plus score(Baseline compared to month 3 (12 weeks), Baseline compared to month 6 (24weeks), month 3 compared to month 6 (12 weeks))
- Change in ADCOMS(Baseline compared to month 3 (12 weeks), Baseline compared to month 6 (24weeks), month 3 compared to month 6 (12 weeks))
- Change in EQ-5D(Baseline compared to month 3 (12 weeks), Baseline compared to month 6 (24weeks), month 3 compared to month 6 (12 weeks))
- Change in ADAS-cog14 total score(Baseline compared to month 3 (12 weeks), Baseline compared to month 6 (24weeks), month 3 compared to month 6 (12 weeks))
- Proportion of subjects with increased K-MMSEII score(Baseline compared to month 3 (12 weeks), Baseline compared to month 6 (24weeks), month 3 compared to month 6 (12 weeks))
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Evaluate the Efficacy and Safety of the Digital Therapeutics Repeech for the Post-Stroke Dysarthria.Post-stroke DysarthriaNCT06670014HAII corp.ltd108
招募中
不适用
Digital Therapeutics on Inhalation Medication Adherence in COPDChronic Obstructive Pulmonary DiseaseNCT05667363China-Japan Friendship Hospital582
已完成
不适用
Digital Therapeutics Smartphone Application for Methamphetamine Use DisorderMethamphetamine AbuseNCT05550493Adai Technology (Beijing) Co., Ltd.100
Unknown
不适用
Study of Efficacy and Safety of WELT-ED for Eating Disorder (WCTP-ED-B-01)Eating DisordersBinge EatingBinge-Eating DisorderNCT06294353WELT corp134
已完成
4 期
Effectiveness of a Digital Therapeutic for Enhancement of the Quality of Life of People with Cancer (lancivis): a randomized controlled trialDRKS00027057GAIA AG604